Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Ocugen Inc (OCGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: OCGN (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 111% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 303.71M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 4 | Beta 4.24 | 52 Weeks Range 0.52 - 1.77 | Updated Date 07/17/2025 |
52 Weeks Range 0.52 - 1.77 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -979.14% |
Management Effectiveness
Return on Assets (TTM) -61.33% | Return on Equity (TTM) -248.97% |
Valuation
Trailing PE - | Forward PE 15.22 | Enterprise Value 318177737 | Price to Sales(TTM) 67.16 |
Enterprise Value 318177737 | Price to Sales(TTM) 67.16 | ||
Enterprise Value to Revenue 70.36 | Enterprise Value to EBITDA -1.95 | Shares Outstanding 292031008 | Shares Floating 287364635 |
Shares Outstanding 292031008 | Shares Floating 287364635 | ||
Percent Insiders 1.6 | Percent Institutions 26.48 |
Upturn AI SWOT
Ocugen Inc
Company Overview
History and Background
Ocugen Inc. was founded in 2013. Originally focused on developing therapies for eye diseases, it later shifted its focus to developing and commercializing a COVID-19 vaccine called Covaxin in the US and Canada.
Core Business Areas
- Biopharmaceutical Development: Development and commercialization of novel biopharmaceutical products.
- Vaccine Development: Focused on developing and commercializing vaccines, particularly Covaxin for COVID-19.
- Ocular Disease Therapies: Researching and developing therapies for various ocular diseases.
Leadership and Structure
Dr. Shankar Musunuri is the Chairman, CEO, and Co-Founder. The company has a typical corporate structure with departments for research, development, manufacturing, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Covaxin: COVID-19 vaccine developed by Bharat Biotech and co-developed and commercialized by Ocugen in the US and Canada (pending regulatory approval). Market share is currently 0% in the US/Canada due to lack of approval. Competitors include Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ).
- OCU400: A novel gene therapy product candidate being developed for retinitis pigmentosa (RP). Phase 1/2 clinical trials are ongoing. There is no current market share and competitors include companies developing therapies for RP.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. The COVID-19 vaccine market is dominated by a few major players. The gene therapy market is rapidly growing with increasing investment and approvals.
Positioning
Ocugen is positioned as a company focused on addressing unmet medical needs in the areas of vaccines and ocular diseases. Its competitive advantage lies in Covaxin's potential profile and its novel gene therapy programs.
Total Addressable Market (TAM)
The COVID-19 vaccine market was estimated to be over $50 billion at its peak. The gene therapy market is expected to reach hundreds of billions in the next decade. Ocugen is positioned to tap into the vaccine market if approved and address the unmet needs in gene therapy.
Upturn SWOT Analysis
Strengths
- Potential for Covaxin in specific populations
- Novel gene therapy platform
- Experienced leadership team
- Partnership with Bharat Biotech
Weaknesses
- Dependence on regulatory approvals for Covaxin
- Limited financial resources compared to larger competitors
- Lack of currently marketed products
- History of volatile stock price.
Opportunities
- Potential for Covaxin to gain approval in US/Canada
- Expansion of gene therapy pipeline
- Strategic partnerships and collaborations
- Government funding and grants
Threats
- Regulatory hurdles for Covaxin
- Competition from established vaccine manufacturers
- Clinical trial failures
- Market acceptance of Covaxin given existing vaccines
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- JNJ
Competitive Landscape
Ocugen faces significant competition from established players in the vaccine and biopharmaceutical industries. Its success depends on differentiating its products and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Ocugen's historical growth has been minimal in terms of revenue, but has seen growth in assets due to fundraising.
Future Projections: Future growth is heavily dependent on the approval and commercialization of Covaxin and the advancement of its gene therapy programs. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for OCU400 and OCU410 and seeking regulatory approvals for Covaxin.
Summary
Ocugen is a high-risk, high-reward biopharmaceutical company. Success is heavily reliant on the approval and commercial success of Covaxin and their gene therapy programs. The company has a partnership with Bharat Biotech, but faces significant competition and regulatory hurdles. Financial performance is weak, and the company relies on equity financing, and is considered very weak at this stage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings, Company press releases, Analyst reports, Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided may not be exhaustive and is subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ocugen Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2014-12-03 | Co-Founder, CEO & Chairman Dr. Shankar Musunuri M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 95 | Website https://www.ocugen.com |
Full time employees 95 | Website https://www.ocugen.com | ||
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.